Project description:This dataset contains peptide array information from 120 patients from 5 different cancer types using classic blinded test/train method. This array is library 1 (GPL17600). A 1:500 dilution of human serum is added to a peptide array (GPL17600). This array is a two-up design, with 10420 peptides printed on the top and bottom of a standard glass microscope slide. Samples were run in duplicate. The average of the duplicates are listed here. 20 train and 20 blinded test samples were run.
Project description:The method DFI-seq was developed to enable identification of differentially expressed genes in uropathogenic E. coli strain UTI89 during growth in human urine and in bladder epithelial cells. By utilising this new method, the aim was to identify novel virulence genes in UTI89. DFI-seq is a combination of differential fluorescence induction (DFI) with next-generation sequencing. DFI-seq was compared to DFI by analysing gene expression of UPEC in human urine and thereby confirming that DFI-seq gives a better overview of gene expression. DFI-seq was hereafter used to look at gene expression in UTI89 while infecting bladder epithelial cells. We demonstrate the usefulness of DFI-seq for identification of genes required for optimal growth of UPEC in human urine, as well as potential virulence genes upregulated during infection of bladder epithelial cells. DFI-seq holds potential for the study of bacterial gene expression in live-animal infection systems.
Project description:Compare difference Global expression profile of hiPSCs between hESCs and human Somatic cells, showing that hiPSCs and hESCs is consistent in lineages and indicated that the induce method is safe and reliable. There are three groups of samples, each group has two repeated samples, hiPSCs respectively compared with hESCs and human Urine-Derived Cells.
Project description:Human plasma samples from CDR = 0 and CDR ≥ 0.5 patients, and serum samples from non-diseased, non-surgical controls were probed onto human protein microarrays to test the utility of a previously established panel of MCI-specific autoantibody (aAB) biomarkers to detect prodromal AD presurgically in individuals admitted into the hospital for hip fracture repair (HFR) surgery.